Ariceum Therapeutics begins phase 1 trial of iodine─123 labelled PARP inhibitor, 123I─ATT001 in patients with recurrent ...
Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, announces that it has commenced a phase 1 first-in-human clinical trial (CITADEL-123) of …